血清基质金属蛋白酶-9、细胞角蛋白19片段及血管内皮细胞生长因子水平与非小细胞肺癌患者顺铂治疗效果的关系  

Association of serum MMP-9,CYRFA21-1,and VEGF levels on cisplatin treatment efficacy in patients with non-small cell lung cancer

作　　者：王海英[1] 吴凯 田胤纯[2] WANG Haiying;WU Kai;TIAN Yinchun(Department of Respiratory and Critical Care Medicine,Affiliated Hospital of Nantong University,Nantong 226001,Jiangsu,China)

机构地区：[1]南通大学附属医院呼吸与危重症医学科,江苏南通226001 [2]泰州市第二人民医院呼吸与危重症医学科,江苏泰州225500

出　　处：《实用医学杂志》2024年第24期3452-3457,共6页The Journal of Practical Medicine

基　　金：国家自然科学基金项目(编号:81503143);南通大学附属医院研究型医院建设经费“揭榜挂帅”研究型医师发展基金(编号:YJxYY202204-Ysco4)。

摘　　要：目的探讨血清基质金属蛋白酶-9(MMP-9)、细胞角蛋白19片段(CYRFA21-1)及血管内皮细胞生长因子(VEGF)水平与非小细胞肺癌患者顺铂化疗治疗效果的关系。方法选取130例于2020年12月至2022年12月期间在南通大学附属医院采用顺铂为基础化疗的晚期驱动基因阴性ⅢB~Ⅳ期非小细胞肺癌患者进行标准的一线治疗,作为观察对象;同期选取100例在我院进行健康体检的人员,作为对照组。比较各组血清MMP-9、CYRFA21-1、VEGF水平,通过顺铂治疗效果将其分为治疗无效组15例,治疗有效组37例;治疗显效组78例,比较各组血清MMP-9、CYRFA21-1、VEGF水平,探索与非小细胞肺癌患者治疗效果的关系。结果非小细胞肺癌患者使用顺铂治疗后,血清MMP-9、CYRFA21-1、VEGF水平均降低(P<0.05);与治疗无效组相比,治疗显效组、治疗有效组患者血清MMP-9、CYRFA21-1、VEGF水平均降低(P<0.05);对比治疗显效组、有效组和治疗无效组患者各项因素分析,经过logistic回归分析显示,MMP-9、CYRFA21-1、VEGF同样是影响非小细胞肺癌患者顺铂治疗效果的危险因素(P<0.05);采用ROC分析得出,血清MMP-9、CYRFA21-1、VEGF单项预测非小细胞肺癌患者使用顺铂治疗效果,预测价值较高(P<0.05)。结论在重症肺炎患者血清中MMP-9、CYRFA21-1、VEGF表达水平升高,MMP-9、CYRFA21-1、VEGF在非小细胞肺癌患者经顺铂治疗后,其表达降低,且与非小细胞肺癌患者顺铂治疗效果有关,临床可通过早期监测血清MMP-9、CYRFA21-1、VEGF水平早期预测治疗效果,以改善患者预后。Objective To investigate the relationship between serum matrix metalloproteinase-9(MMP-9),cytokeratin 19 fragment(CYRFA21-1)and vascular endothelial growth factor(VEGF)levels and cisplatin treatment in patients with non-small cell lung cancer.Methods 130 advanced B-stage non-small cell lung cancer treated with cisplatin in Affiliated Hospital of Nantong University from December 2020 to December 2022 were selected as the study subjects;100 patients with physical examination in our hospital were selected as the control group.By comparing the serum levels of MMP-9,CYRFA21-1 and VE GF in each group,the cisplatin treatment effect was divided into 15 patients and 37 patients in the treatment-effective group,and 78 patients in the treatment-effective group to clarify the relationship between the treatment effect of patients with non-small-cell lung cancer.Results Serum levels of MMP-9,CYRFA21-1 and VEGF were decreased in NSCLC patients after cisplatin treatment(P<0.05).Compared with the ineffective group,serum MMP-9,CYRFA21-1 and VEGF levels in the significantly effective group and the effective group were decreased(P<0.05).Logistic regression analysis showed that MMP-9,CYRFA21-1 and VEGF were also risk factors affecting cisplatin treatment effect in NSCLC patients(P<0.05).ROC analysis showed that serum MMP-9,CYRFA21-1 and VEGF had high predictive value for cisplatin treatment in NSCLC patients(P<0.05).Conclusions MMP-9,CYRFA21-1 and VEGF are highly expressed in the serum of patients with severe pneumonia,and the expression levels of MMP-9,CYRFA21-1 and VEGF are decreased after cisplatin treatment in patients with non-small cell lung cancer,which is related to the cisplatin treatment effect in patients with non-small cell lung cancer.Clinical monitoring of serum levels of MMP-9,CYRFA21-1 and VEGF can predict the therapeutic effect early to improve the prognosis of patients.

关 键 词：非小细胞肺癌 顺铂 基质金属蛋白酶-9 细胞角蛋白19片段 血管内皮细胞生长因子 

分 类 号：R736.2[医药卫生—肿瘤]